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Introduction
Preeclampsia affects 3–5% of pregnant patients and 
is a leading cause of maternal and foetal morbidity-
mortality, particularly in developing countries 
(Walker, 2000). This multisystem disorder can 
include cardiovascular changes, hematologic 
abnormalities, hepatic and renal impairment and 
neurologic manifestations (Williams et al., 2011). 
Visual pathways may also be affected (Roos, 2012). 
Visual symptoms concern up to 25% of the patients 
with severe preeclampsia and 50% of the patients 
with eclampsia (Sunness et al., 1988).  
Posterior Reversible Encephalopathy Syndrome 
(PRES) is a clinical and radiological neurological 
syndrome described in 1980 by Hynchey et al. 
(1996). PRES may develop in the context of renal 
failure, immunosuppressive therapy, porphyria, 
high blood pressure, hypertensive encephalopathy, 
preeclampsia and eclampsia (Hinchey et al., 1996; 
Onder et al., 2007).  
Physiology of PRES is not completely understood 
but hypertension and vasogenic oedema secondary 
to increased capillary permeability are often cited 
(Wagner, 2011; Staykov, 2013). 
PRES associates seizure activity, consciousness 
impairment, headache, nausea and focal neurological 
signs (Hinchey et al., 1996). Visual abnormalities 
are also described with rarely cortical blindness 
(Cunningham et al., 1995). 
PRES may be reversible if adequate and timely 
treatment is initiated but may be permanent, 
recurrent or lead to a fatal outcome if optimal care 
is delayed (Pizon et al., 2015).  No clinical trials 
have evaluated the management of PRES, but rapid 
withdrawal of the trigger appears to hasten recovery 
and to avoid complications such as aggressive 
blood pressure management and withdrawal of the 
offending drug (Roth et al., 2011).
Cerebral imaging abnormalities are often 
symmetric and predominant in the posterior white 
matter (Peng et al., 2008). Oedema is frequently 
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posterior focal lesions in both occipital poles with 
a hyperintense signal on fluid attenuated inversion 
recovery (FLAIR) sequence (Fig. 1.). 
A diagnosis of PRES syndrome including acute 
blindness caused by preeclampsia was confirmed.  
Continuous Intravenous antihypertensive therapy 
(nicardipine) was delivered over the next three days 
under intensive surveillance in the IMC (Intensive 
Maternal Care) department with the aim to optimally 
equilibrate the patient’s blood pressure.  The patient 
regained vision in both eyes within the first 24 hours. 
Blood pressure was definitely normalised after three 
days of antihypertensive treatment.  
A control MRI and electroencephalogram were 
performed two weeks after the caesarean section. 
Both showed a near complete regression of the 
cerebral lesions.
Renal function remained stable within one month 
after delivery. No hypertension persisted.  
The following year, the patient gave birth to 
a live male infant of 3240 g at 37 weeks after an 
uncomplicated pregnancy. The patient received low-
dose aspirin from the beginning of her pregnancy 
until the 36th week of gestation. An elective 
caesarean section was performed. 
Discussion
PRES (Posterior Reversible Encephalopathy 
Syndrome) refers to several pathological conditions 
reported at computed tomography (CT) and at 
magnetic resonance imaging (MRI) (Doelken et al., 
2007). 
We report the case of a 24-year-old patient with 
clinical and radiological presentation of PRES 
complicated by blindness.   
Our aim is to emphasize the critical importance of 
early diagnosis and immediate care in order to avoid 
long term or permanent complications. 
Case report
A 24-year-old, Caucasian woman, gravida 5 para 2 
presented at the Obstetrical Emergencies at 32 weeks 
gestation complaining of headache, abdominal 
pain and absence of foetal movements. Regular 
follow-up of the on-going pregnancy had, so far, 
been uneventful. Before the event, the patient has 
no symptoms, no on-going oedema, no hypertension 
and no visual disturbances. Past medical history was 
unremarkable. 
At the time of admission, blood pressure was 
180/120 mm Hg. No foetal heart activity was noted 
at cardiotocogram and ultrasound. Intrauterine 
foetal death at 32 weeks of gestation was confirmed. 
On physical examination, no peripheral oedema 
was present. A Bishop score of 4 was noted.  
Laboratory tests revealed proteinuria (2 +), a 
mild elevation of uric acid (7mg/dL) and LDH 
(750 UI/L). Hepatic tests and platelets counts were 
normal.  
A diagnosis of severe preeclampsia complicated 
with foetal death was confirmed.  
Urgent labour induction was advised and 
antihypertensive treatment was initiated without 
delay with partial correction of hypertension 
(150/110 mm Hg) by oral nifedipine. Blood pressure 
was continuously monitored. 
One hour after admission, the patient complained 
of sudden bilateral visual loss. Blood pressure had 
peaked at 190/120 mm Hg. IV antihypertensive was 
immediately adapted (nicardipine) and magnesium 
sulphate (4g bolus and then 1g/h by continuous 
infusion) was given. Partial blood pressure reduction 
to 165/95 mm Hg was obtained. 
The patient was counselled on the need to realize 
an emergency caesarean section with the delivery of 
a dead female newborn of 1710 g. 
Subsequent neuro/ophthalmological examination 
of the mother revealed brisk reflexes and bilateral 
papilloedematous discs with macular oedema.  
Brain CT-Scan showed a low-density lesion in 
the right parietal pole. The electroencephalogram 
showed signs of bilateral occipital suffering. 
The magnetic resonance imaging, known to be 
more accurate in such conditions, diagnosed 
Fig. 1. —  MRI performed during episode of blindness: 
posterior lesions in both occipital poles with a hyperintense 
signal (green arrow) on FLAIR sequence. 
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(Burnett et al., 2010). In the past, most cases of 
blindness in preeclampsia and eclampsia were 
commonly attributed to retinal pathology. The 
latter include vascular abnormalities, oedema or 
detachment and acute ischemic optic neuropathy as 
a result of decreased blood supply to the prelaminar 
portion of the optic nerve. Nowadays, more 
emphasis is being placed on the cortical aetiology 
of blindness (Schultz et al., 2005). 
Diagnostic strategy for PRES must be 
standardized. After clinical history, physical 
examination should be immediately followed by 
imaging and blood sample. MRI has a sensitivity 
superior to that of CT (Doelken et al., 2007). 
Laboratory tests should be obtained routinely (Gao 
et al., 2012). Electroencephalography (EEG) has to 
be performed to investigate non-convulsive status 
epilepticus. An early etiologic diagnosis allows 
prompt correction of the cause of PRES. 
Control of hypertension is a crucial part of the 
symptomatic management. Until better evidence 
is available, the choice of antihypertensive should 
depend on the clinician’s experience and familiarity 
with a particular drug. Exceptions are nimodipine, 
magnesium sulphate (although this is indicated 
for women who require an anticonvulsant for 
prevention or treatment of eclampsia), diazoxide 
and ketanserin, which are probably best avoided 
(Duley et al., 2013). Treatment is recommended 
for SBP ≥ 160 mmHg and/or DBP ≥ 110 mmHg 
with a target between 130 and 150 mmHg for SBP, 
and between 80 and 100 mmHg for DBP (Vaughan 
et al., 2010; Ramsay et al., 1999). Immediate and 
acute blood pressure reduction can aggravate the 
cerebral perfusion pressure alterations and promote 
ischemia (Varon et al., 2010). A decrease of 10 to 
20 mmHg every 10 to 20 min has been suggested 
by some authors (Dennis et al., 2012). Appropriate 
medications include nicardipine and labetolol 
(Varon et al., 2010). The literature is not clear 
whether nifedipine can increase angio-oedema 
and triggered the PRESS. Nicardipine has higher 
selectivity for blood vessels than the myocardium 
and causes less reflex tachycardia than nifedipine. 
Furthermore, the dosage of nicardipine can be more 
easily adjusted. The use of thiopental, valproate or 
phenitoin was reported only for status epilepticus 
(Demirel et al., 2012). 
Correction of the cause is crucial in order to 
decrease the risk of ischemia or bleeding and to 
avoid permanent disability or death. 
The only etiologic treatment of preeclampsia 
is foetus and placenta delivery. Timing of 
delivery must take into account the gestational 
age, severity of preeclampsia, as well as maternal 
and foetal conditions. Current treatments aim at 
that share the same clinical and radiological 
presentations and result in the development of 
neurological deficit (Hinchey et al., 1996).  
The prevalence of this complication is unknown. 
There is a marked female predominance that may 
reflect some of the underlying causes. Hypertension 
is the second most common associated condition 
after toxic agents (cancer chemotherapy agents 
such as cysplatin, anti-angiogenic agents such as 
Bevacizumab,... ), the latter being present in 6% 
to 72 % of cases (Bartynski et al., 2006; Lee et 
al., 2008). Preeclampsia is found in 7% to 20% of 
patient with PRES (Hinchey et al., 1996; Schwartz, 
2000). 
The precise pathophysiology of PRES remains 
unclear. Cerebral vasospasm with secondary 
ischemic injury or vasogenic oedema due to 
increased capillary permeability are both suggested 
(Servillo et al., 2007; Staykov et al., 2013). 
Recently, single-photon emission tomography 
studies supported the finding that elevated capillary 
permeability and vasogenic oedema are present in 
patients with cortical blindness (McCormick et al., 
1999). 
Despite the dramatic neurological and radiological 
picture, the syndrome may be reversible, as 
suggested by its name (Schwartz, 2002). The rate of 
reversibility varies widely in published series (from 
35% to 100%). Reversibility, whether complete or 
partial, is not always mentioned in the literature 
(Hinchey, 1996). Among patients with a follow-up 
CT or MRI, 49% to 75% have a resolution of the 
initial abnormalities within 5 days to 17 months 
(Casey et al., 2010). However, if not adequately 
and quickly treated, there may remain permanent 
neurological deficits, most frequently under the 
form of epilepsy (Burnett et al., 2010). 
Permanent neurological abnormalities are related 
to ischemia and/or bleeding. Death is reported in 
up to 15% of the patients with PRES (Servillo et 
al., 2003, Lee, 2008; Striano et al., 2010). Delayed 
identification or care of the patient appears to be 
involved in most patients with a fatal outcome.  
The combination of suggestive clinical 
manifestations and typical radiological criteria 
confirm the diagnosis of PRES. Neurological 
manifestations such as headache, nausea, vomiting, 
confusion, behavioural disorders, impaired level of 
consciousness (from somnolence to coma), mental 
status changes (confusion, amnesia, impaired 
concentration, lethargy), and seizures may occur 
(Hinchey et al., 1996).  
Visual abnormalities (blurred vision, 
hemianopsia…) are found in 26 % to 67% (Hinchey 
et al., 1996; Bartynski et al., 2005) of the patients 
with PRES and cortical blindness in 8% to 33 % 
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Conclusion
We report a case of reversible posterior 
encephalopathy syndrome (PRES) secondary to 
preeclampsia complicated by sudden blindness. 
The patient regained vision in both eyes and had 
a favourable outcome with no sequelae after 
appropriate treatment. 
This case highlights the utmost importance of 
an early diagnosis followed by immediate and 
appropriate care. Both parameters optimize the 
chance of complete reversibility and limit the risk of 
neurological sequelae or potential fatal evolution.
Our observation, combined with other reported 
cases, leads some authors to suggest that a better 
name may be “potentially reversible encephalopathy 
syndrome”. 
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